Jazz Phase III Success With Xywav In Idiopathic Hypersomnia Strengthens A Valuable Franchise
Executive Summary
The company plans to file for approval in the expanded indication, for which there are currently no approved therapies.
You may also be interested in...
Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy
Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.
Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.